NCT00038168View on ClinicalTrials.gov

Intravenous Estramustine With Taxol in Hormone Refractory Prostate Adenocarcinoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

June 30, 2000

Primary Completion Date

January 31, 2003

Study Completion Date

January 31, 2003

Conditions
Prostate Cancer
Interventions
DRUG

Estramustine

Intravenous dose

DRUG

Taxol

Intravenous dose

Trial Locations (1)

77030

MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT00038168 - Intravenous Estramustine With Taxol in Hormone Refractory Prostate Adenocarcinoma | Biotech Hunter | Biotech Hunter